Results 181 to 190 of about 357,544 (339)

A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.

New England Journal of Medicine, 2004
G. Stone, S. Ellis, D. Cox, J. Hermiller, C. O'shaughnessy, J. Mann, M. Turco, R. Caputo, P. Bergin, Joel D Greenberg, J. Popma, M. Russell   +11 more
semanticscholar   +1 more source

Comparison Between Upfront Surgery and Preoperative Chemotherapy for CY1P0 Gastric Cancer: A Japanese Sub‐Analysis of CONVO‐GC‐1

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Radical gastrectomy, followed by adjuvant chemotherapy has been a common practice in Japan for peritoneal lavage cytology‐positive (CY1) but peritoneal dissemination‐negative (P0) stage IV gastric cancer. This study aimed to clarify the differences in treatment outcomes between upfront surgery and preoperative chemotherapy, followed
Kenichiro Furukawa, Itaru Yasufuku, Hironori Ishigami, Masahiro Yura, Takanobu Yamada, Shigeaki Baba, Takeshi Kubota, Erina Nagai, Seito Fujibayashi, Mitsumasa Yoshida, Takahiro Kinoshita, Nobuhisa Matsuhashi, Masanori Terashima   +12 more
wiley   +1 more source

Cisplatin/Paclitaxel/Intraperitoneal Paclitaxel Regimen [PDF]

, 2020
openaire   +1 more source

Preoperative Gemcitabine/Nab‐Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer: A Comparative Analysis With Preoperative Chemoradiation Therapy Using Gemcitabine Alone

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Although NCCN guidelines recommend preoperative therapy for borderline resectable pancreatic cancer (BR‐PC), it is still unclear which regimen is better. The study objective was to elucidate the prognostic significance of neoadjuvant chemoradiotherapy (NACRT) with gemcitabine/nab‐paclitaxel (GnP‐RT) compared to gemcitabine alone ...
Hirofumi Akita, Hidenori Takahashi, Yousuke Mukai, Masahiko Kubo, Shinichiro Hasegawa, Masayoshi Yasui, Takeshi Omori, Hiroshi Miyata, Hiroshi Wada, Kunihito Gotoh   +9 more
wiley   +1 more source

Comparison of the Clinical Effects of Paclitaxel and Paclitaxel plus Oxaliplatin as the Second-line Treatment of Advanced Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2009
Background and objective Second-line chemotherapy with taxanes for the patients with non-small cell lung cancer (NSCLC), who had disease recurrence or failure in previously treated with platinum-based chemotherapy, has been shown to be effective. Besides
Tianqing CHU, Hao LIN, Jie SHEN, Runbo ZHONG, Baohui HAN   +4 more
doaj  

Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization

Annals of Gastroenterological Surgery, EarlyView.
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya, Koichi Yagi, Yoshifumi Baba   +2 more
wiley   +1 more source

Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells.

Nanomedicine : nanotechnology, biology, and medicine, 2016
M. Kim, Matthew J. Haney, Yuling Zhao, V. Mahajan, I. Deygen, N. Klyachko, Eli Inskoe, A. Piroyan, Marina Sokolsky, Onyi Okolie, S. Hingtgen, A. Kabanov, E. Batrakova   +12 more
semanticscholar   +1 more source

Cancer therapy‐induced ototoxicity: Current challenges and emerging management strategies

Animal Models and Experimental Medicine, EarlyView.
This review comprehensively examines the key risk factors for cancer therapy‐induced ototoxicity, including cumulative drug dose, genetic susceptibility, and combined treatment regimens. It highlights current challenges in ototoxicity monitoring, such as insufficient timeliness and limited clinical adoption, and advocates for standardized auditory ...
Yuqi Huang, Baoying Xu, Xinru Chen, Yu Chen, Dehong Yu   +4 more
wiley   +1 more source

Forkhead box K2 modulates epirubicin and paclitaxel sensitivity through FOXO3a in breast cancer [PDF]

, 2015
Lam, EW
core   +1 more source

Therapeutic Applications of Stimuli‐Based Release and Engineering of Extracellular Vesicles

Advanced NanoBiomed Research, EarlyView.
This review summarizes the effects of endogenous and exogenous stimuli, their effects on the natural release of extracellular vesicles, as well as their uptake and release. It also gives an overview of stimuli‐responsive EVs and their therapeutic applications. Extracellular vesicles (EVs), nano‐ to microsized lipid bilayer membrane‐bound particles, are
Gloria Kemunto, Kristen Dellinger
wiley   +1 more source